CO4970730A1 - Tetrahidro prostaglandinas aromaticas c16-c20 sustituidas utilies como agonistas fp - Google Patents
Tetrahidro prostaglandinas aromaticas c16-c20 sustituidas utilies como agonistas fpInfo
- Publication number
- CO4970730A1 CO4970730A1 CO98051813A CO98051813A CO4970730A1 CO 4970730 A1 CO4970730 A1 CO 4970730A1 CO 98051813 A CO98051813 A CO 98051813A CO 98051813 A CO98051813 A CO 98051813A CO 4970730 A1 CO4970730 A1 CO 4970730A1
- Authority
- CO
- Colombia
- Prior art keywords
- ring
- aliphatic ring
- aromatic
- alkyl
- heteroalkyl
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003949 imides Chemical class 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
La presente invención se relaciona con un compuesto quetiene la estructura:donde a) R1 es CO2 H, C(O)NHOH, CO2 R5 , CH2 OH, S(O)2 R5 , C(O)NHR5 , C(O)NHS(O)2 R5 o tetrazol; donde R5 es alquilo, heteroalquilo, anillo alifático carbocíclico, anillo alifático heterocíclico, anillo aromático o anillo heteroaromático;(b) R2 es H o alquilo inferior;(c) X es NR6 R7 , OR8 , SR9 , S(O)R9 ; ó S(O)2 R9 ; donde R6 , R7 y R8 son independientemente seleccionados del grupo consistente de H, acilo, alquilo, heteroalquilo, anillo alifático carbocíclico, anillo alifático heterocíclico, anillo aromático o anillo heteroaromático; y donde R9 es alquilo, eteroalquilo, anillo alifático carbocíclico, anillo alifático heterocíclico, anillo aromático o anillo heteroaromático;(d) R3 y R4 son independientemente H, CH3 , C2 H5 , OR10 , SR10 u OH, excepto que R3 y R4 no sean OH; donde R10 es alquilo, heteroalquilo, anillo alifático carbocíclico, anillo alifático heterocíclico, anillo aromático o anillo heteroaromático, teniendo R10 desde 1 hasta 8 átomos miembros;(e) Y es (CH2 )n ; siendo n un entero desde O hasta 3;(f) Z es anillo alifático carbocíclico, anillo alifático heterocíclico, anillo heteroaromático monocíclico o fenilo sustituido cuando n es 0, 2 ó 3; y Z es anillo alifático carbocíclico, anillo alifático heterocíclico o fenilo sustituido cuando n es 1; ycualquier isómero óptico, diestereómero, enantiómero de la estructura anterior o una sal farmacéuticamente aceptable o amida biohidrolizable, éster o imida de ellos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5824697P | 1997-09-09 | 1997-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4970730A1 true CO4970730A1 (es) | 2000-11-07 |
Family
ID=22015602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98051813A CO4970730A1 (es) | 1997-09-09 | 1998-09-09 | Tetrahidro prostaglandinas aromaticas c16-c20 sustituidas utilies como agonistas fp |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6107338A (es) |
| EP (1) | EP1021402B1 (es) |
| JP (1) | JP2001515883A (es) |
| KR (1) | KR20010023837A (es) |
| CN (1) | CN1269785A (es) |
| AR (1) | AR017077A1 (es) |
| AT (1) | ATE310721T1 (es) |
| AU (1) | AU741014B2 (es) |
| BR (1) | BR9811779A (es) |
| CA (1) | CA2303763C (es) |
| CO (1) | CO4970730A1 (es) |
| DE (1) | DE69832513T2 (es) |
| ES (1) | ES2253826T3 (es) |
| HU (1) | HUP0004436A3 (es) |
| IL (1) | IL134792A0 (es) |
| NO (1) | NO20001142L (es) |
| NZ (1) | NZ503736A (es) |
| PE (1) | PE123199A1 (es) |
| PL (1) | PL339213A1 (es) |
| SK (1) | SK3362000A3 (es) |
| TR (1) | TR200000670T2 (es) |
| WO (1) | WO1999012896A1 (es) |
| ZA (1) | ZA988231B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015608A1 (en) * | 1998-09-14 | 2000-03-23 | Ono Pharmaceutical Co., Ltd. | φ-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT |
| ES2232434T3 (es) * | 1999-03-05 | 2005-06-01 | Duke University | Analogos de prostaglandinas c-16 fp selectivas insaturadas. |
| EP1202999B1 (en) * | 1999-08-04 | 2003-06-18 | The Procter & Gamble Company | Novel 2-decarboxy-2-phosphinico prostaglandin f analogs |
| US20020172693A1 (en) * | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| US6376533B1 (en) * | 2000-10-20 | 2002-04-23 | Allergan Sales, Inc. | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| US6586462B2 (en) | 2000-10-20 | 2003-07-01 | Allergan, Inc. | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| US6531504B2 (en) * | 2001-05-17 | 2003-03-11 | Allergan, Inc. | Prostanoic acid derivatives as agents for lowering intraocular pressure |
| US7631336B2 (en) | 2004-07-30 | 2009-12-08 | Broadband Itv, Inc. | Method for converting, navigating and displaying video content uploaded from the internet to a digital TV video-on-demand platform |
| US7590997B2 (en) | 2004-07-30 | 2009-09-15 | Broadband Itv, Inc. | System and method for managing, converting and displaying video content on a video-on-demand platform, including ads used for drill-down navigation and consumer-generated classified ads |
| US20060135609A1 (en) | 2004-10-21 | 2006-06-22 | Duke University | Ophthamological drugs |
| US20070254920A1 (en) * | 2006-04-26 | 2007-11-01 | Aerie Pharmaceuticals, Inc. | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| AU2009340420A1 (en) | 2008-10-29 | 2010-08-26 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| US8623918B2 (en) * | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| CA2850987C (en) | 2011-10-17 | 2019-10-15 | Biotheryx, Inc. | Substituted biaryl alkyl amides |
| CN109528721B (zh) | 2013-03-15 | 2021-10-01 | 爱瑞制药公司 | 联合治疗 |
| CN104140410B (zh) * | 2013-05-09 | 2017-12-15 | 江苏豪森药业集团有限公司 | 鲁比前列酮的制备方法 |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| CA3035566A1 (en) | 2016-08-31 | 2018-03-08 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
| CN110506037A (zh) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | 芳基环丙基-氨基-异喹啉酰胺化合物 |
| US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4011262A (en) * | 1972-07-13 | 1977-03-08 | Pfizer Inc. | 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series |
| IL43571A (en) * | 1972-11-08 | 1977-08-31 | Pfizer | Omega-pentanorprostaglandins and their preparation |
| JPS5720305B2 (es) * | 1973-02-28 | 1982-04-27 | ||
| DE2365101A1 (de) * | 1973-12-21 | 1975-07-10 | Schering Ag | Neue prostansaeurederivate und verfahren zu ihrer herstellung |
| DE2460990A1 (de) * | 1974-12-21 | 1976-07-01 | Hoechst Ag | Neue prostaglandin-analoga und verfahren zu ihrer herstellung |
| DE2737808A1 (de) * | 1976-08-27 | 1978-03-16 | Pfizer | 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine |
| US4621100A (en) * | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
| DE4024347A1 (de) * | 1990-07-27 | 1992-01-30 | Schering Ag | Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
| US5545665A (en) * | 1993-12-28 | 1996-08-13 | Allergan | Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents |
| US6169111B1 (en) * | 1995-06-07 | 2001-01-02 | Alcon Laboratories, Inc. | Conformationally rigid aryl prostaglandins for use in glaucoma therapy |
| WO1997023225A1 (en) * | 1995-12-22 | 1997-07-03 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
| US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
| US5741810A (en) * | 1996-02-29 | 1998-04-21 | Allergan | Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents |
| DE69714698T2 (de) * | 1996-06-10 | 2002-12-05 | Sucampo Ag | Endothelin-antagonisten |
| DE69714274T3 (de) * | 1996-09-17 | 2006-06-01 | Asahi Glass Co., Ltd. | Fluorierte prostaglandinderivate und medikamente |
| AU5436198A (en) * | 1996-11-12 | 1998-06-03 | Alcon Laboratories, Inc. | 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension |
| AU5258698A (en) * | 1996-11-12 | 1998-06-03 | Alcon Laboratories, Inc. | 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension |
| AU725677B2 (en) * | 1997-05-09 | 2000-10-19 | Mount Sinai School Of Medicine Of The City University Of New York, The | 8-iso-prostaglandins for glaucoma therapy |
-
1998
- 1998-09-04 TR TR2000/00670T patent/TR200000670T2/xx unknown
- 1998-09-04 ES ES98944720T patent/ES2253826T3/es not_active Expired - Lifetime
- 1998-09-04 PL PL98339213A patent/PL339213A1/xx unknown
- 1998-09-04 US US09/148,374 patent/US6107338A/en not_active Expired - Lifetime
- 1998-09-04 SK SK336-2000A patent/SK3362000A3/sk unknown
- 1998-09-04 WO PCT/US1998/018340 patent/WO1999012896A1/en active IP Right Grant
- 1998-09-04 IL IL13479298A patent/IL134792A0/xx unknown
- 1998-09-04 BR BR9811779-3A patent/BR9811779A/pt not_active IP Right Cessation
- 1998-09-04 KR KR1020007002512A patent/KR20010023837A/ko not_active Application Discontinuation
- 1998-09-04 AT AT98944720T patent/ATE310721T1/de not_active IP Right Cessation
- 1998-09-04 NZ NZ503736A patent/NZ503736A/en unknown
- 1998-09-04 CA CA002303763A patent/CA2303763C/en not_active Expired - Lifetime
- 1998-09-04 HU HU0004436A patent/HUP0004436A3/hu unknown
- 1998-09-04 AU AU92194/98A patent/AU741014B2/en not_active Expired
- 1998-09-04 JP JP2000510708A patent/JP2001515883A/ja not_active Withdrawn
- 1998-09-04 DE DE69832513T patent/DE69832513T2/de not_active Expired - Lifetime
- 1998-09-04 EP EP98944720A patent/EP1021402B1/en not_active Expired - Lifetime
- 1998-09-04 CN CN98808989A patent/CN1269785A/zh active Pending
- 1998-09-08 AR ARP980104481A patent/AR017077A1/es unknown
- 1998-09-08 PE PE1998000845A patent/PE123199A1/es not_active Application Discontinuation
- 1998-09-09 ZA ZA988231A patent/ZA988231B/xx unknown
- 1998-09-09 CO CO98051813A patent/CO4970730A1/es unknown
-
2000
- 2000-03-06 NO NO20001142A patent/NO20001142L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU9219498A (en) | 1999-03-29 |
| CA2303763A1 (en) | 1999-03-18 |
| EP1021402B1 (en) | 2005-11-23 |
| ES2253826T3 (es) | 2006-06-01 |
| IL134792A0 (en) | 2001-04-30 |
| WO1999012896A1 (en) | 1999-03-18 |
| DE69832513D1 (de) | 2005-12-29 |
| DE69832513T2 (de) | 2006-07-13 |
| NZ503736A (en) | 2002-06-28 |
| SK3362000A3 (en) | 2000-10-09 |
| ZA988231B (en) | 1999-03-09 |
| TR200000670T2 (tr) | 2000-11-21 |
| NO20001142L (no) | 2000-05-04 |
| HUP0004436A3 (en) | 2001-09-28 |
| EP1021402A1 (en) | 2000-07-26 |
| US6107338A (en) | 2000-08-22 |
| KR20010023837A (ko) | 2001-03-26 |
| BR9811779A (pt) | 2000-09-12 |
| CN1269785A (zh) | 2000-10-11 |
| ATE310721T1 (de) | 2005-12-15 |
| AR017077A1 (es) | 2001-08-22 |
| AU741014B2 (en) | 2001-11-22 |
| PE123199A1 (es) | 2000-02-02 |
| CA2303763C (en) | 2007-04-24 |
| PL339213A1 (en) | 2000-12-04 |
| JP2001515883A (ja) | 2001-09-25 |
| NO20001142D0 (no) | 2000-03-06 |
| HUP0004436A2 (hu) | 2001-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4970730A1 (es) | Tetrahidro prostaglandinas aromaticas c16-c20 sustituidas utilies como agonistas fp | |
| CO4970731A1 (es) | Tetrahidro prostaglandinas c16-c29 sustituidas utiles como agonistas fp | |
| CO4970733A1 (es) | Tetrahidro prostaglandinas aromaticas c16-c20 sustituidas utiles como agonistas fp | |
| RU2291860C3 (ru) | Производные 2-оксо-1-пирролидина, способ их получения и применения | |
| HUT61742A (en) | Process for producing cyclic amide derivatives and pharmaceutical compositions comprising same | |
| UY25987A1 (es) | Procedimiento para preparar complejo del inhibidor de ras-fa rnesiltransferasa y sulfobutileter-7-beta-ciclodextrina o 2- hidroxipropil-beta-ciclodextrina y método | |
| ES2082026T3 (es) | Derivados de hidantoina. | |
| ATE158506T1 (de) | Okulare hypotensive 2-dekarboxyl-2-aminoalkyl- prostaglandine | |
| MX9201805A (es) | Derivados de n-imidazolilo de indol substituido, procedimiento para su preparacion y composicion farmaceutica que los contiene. | |
| CO5280081A1 (es) | Antibacterianos de piperidiniloxi oxazolidinona, composicion farmaceutica que los comprende y proceso para su preparacion | |
| AR030197A1 (es) | Compuesto n-sustituido que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento | |
| CO4970802A1 (es) | Compuesto bencimidazol-5 sustituido con estabilidad mejorada | |
| AR020063A1 (es) | Oximil e hidroxilamino c, prostaglandinas utiles como agonistas de receptores fp y su uso para fabricar medicamentos para tratar oseos y glaucoma. | |
| UA43338C2 (uk) | Похідні бензолу | |
| WO1998053790A3 (en) | Compounds that inhibit the binding of vascular endothelial growth factor to its receptors | |
| NZ506855A (en) | C11 Oxymyl and hydroxylamino prostaglandins useful as FP agonists | |
| FI923492A (fi) | Indolderivat, deras framstaellning och anvaendning. | |
| PT728748E (pt) | Novos derivados da benzodiazepina | |
| MX9200178A (es) | DERIVADOS DE N-IMIDAZOLILO DE CICLOHEPT (b) INDOL Y TETRAHIDROCARBAZOL SUBSTITUIDOS Y COMPOSICION FARMACEUTICA QUE LOS CONTIENE. | |
| AR023528A1 (es) | Derivados de ciclobuten-3,4-diona, su preparacion y su aplicacion en terapeutica | |
| AR008950A1 (es) | Nuevos compuestos derivados del benzoperhidroisoindol, procedimiento para prepararlos, los intermediarios de sintesis y los procedimientos paraprepararlos, las composiciones farmaceuticas que los contienen, la utilizacion de dichos compuestos para preparar dichas composiciones y las composiciones | |
| CO4910165A1 (es) | Procedimiento para elaboracion de derivados de 2-amino-2- imidazolina, guanidina y 2-amino-3,4,5,6-tetrahidropirimidi- na | |
| ATE264320T1 (de) | 5-aminoalkyl- und 5-aminocarbonylsubstituierte indole | |
| PE20010131A1 (es) | Agentes inmunopotenciadores | |
| MX9200510A (es) | Procedimiento de preparacion de derivados de benzofurano, benzotiofeno, indol e indolicina, productos resulantes y composiciones que los contienen. |